JP2023503229A5 - - Google Patents
Info
- Publication number
- JP2023503229A5 JP2023503229A5 JP2022524592A JP2022524592A JP2023503229A5 JP 2023503229 A5 JP2023503229 A5 JP 2023503229A5 JP 2022524592 A JP2022524592 A JP 2022524592A JP 2022524592 A JP2022524592 A JP 2022524592A JP 2023503229 A5 JP2023503229 A5 JP 2023503229A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/120054 | 2019-11-21 | ||
| CN2019120054 | 2019-11-21 | ||
| PCT/CN2020/130059 WO2021098769A1 (en) | 2019-11-21 | 2020-11-19 | Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023503229A JP2023503229A (ja) | 2023-01-27 |
| JPWO2021098769A5 JPWO2021098769A5 (https=) | 2023-11-29 |
| JP2023503229A5 true JP2023503229A5 (https=) | 2023-11-29 |
Family
ID=75981033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022524592A Pending JP2023503229A (ja) | 2019-11-21 | 2020-11-19 | 抗ｏｘ４０抗体とマルチキナーゼ阻害剤とによる癌の治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230022859A1 (https=) |
| EP (1) | EP4061421A4 (https=) |
| JP (1) | JP2023503229A (https=) |
| CN (1) | CN114728063B (https=) |
| WO (1) | WO2021098769A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112566935B (zh) | 2018-05-23 | 2024-12-13 | 百济神州有限公司 | 抗ox40抗体和使用方法 |
| WO2023155777A1 (en) * | 2022-02-15 | 2023-08-24 | Beigene (Suzhou) Co., Ltd. | N- [ (6-bromopyridin-3-yl) methyl] -2-methoxyethan-1-amine salts and preparation thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0816064B8 (pt) * | 2007-08-29 | 2021-05-25 | Methylgene Inc | composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica |
| CN102010407A (zh) * | 2010-11-16 | 2011-04-13 | 上海科胜药物研发有限公司 | 一种合成达沙替尼的新方法 |
| SMT201800503T1 (it) * | 2013-03-18 | 2018-11-09 | Janssen Pharmaceuticals Inc | Anticorpi anti-cd (ox40) umanizzati e loro usi |
| KR20180011839A (ko) * | 2015-06-08 | 2018-02-02 | 제넨테크, 인크. | 항-ox40 항체를 이용한 암의 치료 방법 |
| GB201519481D0 (en) * | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| CN111542544A (zh) * | 2017-11-01 | 2020-08-14 | 百时美施贵宝公司 | 用于治疗癌症的免疫刺激性激动性抗体 |
| MX2020012081A (es) * | 2018-05-11 | 2021-04-28 | Wuxi Biologics Shanghai Co Ltd | Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso. |
| CN112566935B (zh) * | 2018-05-23 | 2024-12-13 | 百济神州有限公司 | 抗ox40抗体和使用方法 |
-
2020
- 2020-11-19 US US17/778,677 patent/US20230022859A1/en not_active Abandoned
- 2020-11-19 JP JP2022524592A patent/JP2023503229A/ja active Pending
- 2020-11-19 WO PCT/CN2020/130059 patent/WO2021098769A1/en not_active Ceased
- 2020-11-19 CN CN202080080793.6A patent/CN114728063B/zh active Active
- 2020-11-19 EP EP20891278.2A patent/EP4061421A4/en not_active Withdrawn